期刊
CURRENT OPINION IN PHARMACOLOGY
卷 6, 期 3, 页码 257-262出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2006.03.002
关键词
-
资金
- NHLBI NIH HHS [R01 HL079904, R01-HL55330, R01-HL60234] Funding Source: Medline
- NIAID NIH HHS [R01-AI42365] Funding Source: Medline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060234, R01HL079904, R01HL055330] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER
Carbon monoxide (CO) offers potential therapeutic avenues in the treatment of lung disorders. CO arises endogenously from heme degradation, catalyzed by the heme oxygenase enzymes. In cell culture, CO exerts potent anti-inflammatory, anti-apoptotic and anti-proliferative effects by modulating intracellular signaling pathways. In vivo, CO confers tissue protection in animal models of lung disease, including those with oxidative and inflammatory lung injury and ischemia/ reperfusion injury. Furthermore, low-dose CO ameliorates vascular injury and reduces the rejection rate of lung and vascular grafts. Recent advances include the observation that CO protects the lung in models of bleomycin-induced lung fibrosis and ventilator-induced lung injury. Despite the success of CO therapy in animal models, the utility of CO as therapy in humans remains uncertain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据